Get started
Author

Sam Scott

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
2022 · Brian J. Willett, Joe Grove, et al. · Nature Microbiology · 812
PDF
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 125
Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis
2023 · Christopher A. Martin, Joshua Nazareth, et al. · EClinicalMedicine · 31
PDF
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
2022 · Brian J. Willett, Joe Grove, et al. · Nature Microbiology · 29
PDF
Immunological imprinting of humoral immunity to SARS-CoV-2 in children
2023 · Alexander C. Dowell, Tara Lancaster, et al. · Nature Communications · 25
PDF
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
2022 · Helen Parry, Rachel Bruton, et al. · Cancer Cell · 24
PDF
Omicron BA.2.86 cross-neutralising activity in community sera from the UK
2023 · Brian J Willett, Nicola Logan, et al. · The Lancet · 16
PDF
SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity
2022 · Maria Manali, Laura A Bissett, et al. · The Journal of Infectious Diseases · 14
PDF
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people
2022 · Helen Parry, Rachel Bruton, et al. · Cell Reports Medicine · 13
PDF
Increase in SARS-CoV-2 Seroprevalence in UK Domestic Felids Despite Weak Immunogenicity of Post-Omicron Variants
2023 · Grace B. Tyson, Sarah Jones, et al. · Viruses · 12
PDF
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
2025 · Jonathan A Cook, Piers E M Patten, et al. · The Lancet Haematology · 9
mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273
2022 · Alexander C. Dowell, Annabel A. Powell, et al. · Frontiers in Immunology · 5
Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024
2025 · Mhairi J. McCormack, Sam Scott, et al. · EBioMedicine · 3
PDF
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
2024 · Thomas Roberts, Grace Uwenedi, et al. · Blood Cancer Journal · 2
PDF
The impact of ethnicity on longitudinal humoral and cellular immune responses to SARS-CoV-2 booster vaccination
2026 · Christopher A. Martin, Joshua Nazareth, et al. · Scientific Reports · 1
PDF
Robust generation of neutralising antibodies against Omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years
2023 · Helen Parry, Rachel Bruton, et al. · Journal of Infection · 1
PDF
SARS-CoV-2Infection Following Booster Vaccination: Prevalence, Immunological and Proteomic Correlates, Symptom Profiles and Household Transmission in a Longitudinal Healthcare Worker Cohort (BE-DIRECT)
2026 · Daniel Pan, Christopher Andrew Martin, et al. · SSRN Electronic Journal
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (Nature Microbiology, (2022), 7, 8, (1161-1179), 10.1038/s41564-022-01143-7)
2022 · Brian J. Willett, Joe Grove, et al. · Newcastle University ePrints (Newcastle Univesity)
Works count: 19
Citation count: 1,100
H-index: 10
I10-index: 10
Year
Topic
Type